

Project ECHO for Interstitial Lung Disease

Wednesday, January 21, 2026, 7am-8am ET

Medical Director	Robert Hallowell, MD
Principal Investigator	Aliaa Barakat, PhD
Didactic Speaker	Barry Shea, MD
Discussion Facilitator	Robert Hallowell, MD
Target Audience	The series is designed for pulmonologists, radiologists and other health providers who care for people with ILD.

In accordance with HIPAA: All PHI will be de-identified during the session.

Time	Didactic Presentation / Case Discussion	Presenter / Facilitator
7:00am-7:05am	Announcements and Introductions	Aliaa Barakat, PhD Robert Hallowell, MD
7:05am-7:25am	Didactic: New and Emerging Treatments for Pulmonary Fibrosis	Barry Shea, MD
7:25am-8:00am	Case Presentation and Discussion	Robert Hallowell, MD
8am	Closing Remarks	Aliaa Barakat, PhD

Didactic Learning Objectives:

1. Summarize the key findings from data supporting the use of pirfenidone, nintedanib, and nerandomilast for IPF and PPF.
2. Compare the major risks and side effects of the different antifibrotic options.
3. Explain how nerandomilast can be incorporated into treatment algorithms for IPF and PPF.

ECHO case discussions are intended solely for educational purposes and are not meant to serve as a consultation or as a mechanism for providing formal recommendations on treatment and other management decisions, which remain the sole responsibility of the treating provider.

This session will be audio and video recorded.
Your participation confirms your consent to this recording.

**Chobanian & Avedisian School of Medicine**

Barry M. Manuel Center for Continuing Education



In support of improving patient care, this activity has been planned and implemented by the ILD Collaborative and Boston University Chobanian & Avedisian School of Medicine. Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

**American Board of Internal Medicine Maintenance of Certification (MOC) Part 2 Credit**

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 22.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

American Board of Pathology Maintenance of Certification (MOC) Part 2 Credit

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 22.0 MOC points in the American Board of Pathology's (ABPath) Maintenance of Certification (MOC) program. Credit type: Lifelong Learning (CME).

By participating and claiming credit, you grant the Center for Continuing Education permission to submit your information to the ACCME, the conduit to the ABIM and ABPath.

Physician Accreditation

Boston University Chobanian & Avedisian School of Medicine designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Accreditation

Nursing Contact Hours: 1.0, all of which is eligible for pharmacology credit.

This activity is supported by the ILD Collaborative and by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

This session will be audio and video recorded.
Your participation confirms your consent to this recording.

Disclosure Policy

Boston University Chobanian & Avedisian School of Medicine asks all individuals involved in the development and presentation of Accredited Continuing Education activities to disclose all financial relationships with ineligible companies. This information is disclosed to all activity participants prior to the start of the educational activity. Boston University Chobanian & Avedisian School of Medicine has procedures to mitigate all relevant financial relationships with ineligible companies. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.

None of the following planners / presenters for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Aliaa Barakat, PhD, Katharine Black, MD, Fiona Gibbons, MD, and Grace Peloquin, MD.

The following planners / presenters listed below have disclosed that they have a relevant financial relationship with an ineligible company.

Name	Disclosure of Relevant Financial Relationship
Leo Ginns, MD	Dr. Ginns is a clinical trial site principal investigator for United Therapeutics.
Robert Hallowell, MD	Dr. Hallowell has served on advisory boards and as an investigator for Boehringer Ingelheim. He has served as a consultant and an investigator for Vicore. He has also been a consultant for Merck and receives authorship fees from Up-to-Date and Dynamed.
Sydney Montesi, MD	Dr. Montesi is a consultant and on the clinical adjudication committee for AbbVie. She is also a consultant for Amgen, Accendatech, and Mediar Therapeutics. She receives research funding from Boehringer Ingelheim, and Pliant Therapeutics via her institution. She also receives authorship fees from Wolters Kluwer.
Barry Shea, MD	Dr. Shea is a clinical trial site principal investigator for Boehringer Ingelheim, Bristol Myers Squibb, and Mediar Therapeutics. He has served as a consultant for Continuum Therapeutics, Radius Health, and United Therapeutics.

All of the relevant financial relationships listed for these individuals have been mitigated.

Accreditor Disclosure:

Michael Burk, Senior Operations Manager for Boston University Chobanian & Avedisian School of Medicine Center for Continuing Education, has no relevant financial relationships to disclose.

Accreditor Disclosure:

The faculty does plan on discussing unlabeled/investigational uses of a commercial product.

This session will be audio and video recorded.
Your participation confirms your consent to this recording.